Symbicort vs Tezspire
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Symbicort | US Tezspire | |
|---|---|---|
| Generic name | budesonide/formoterol | tezepelumab |
| Drug class | ICS/LABA Inhaler | TSLP Blocker (Biologic) |
| Treats | Asthma, COPD | Severe asthma |
| Category | Respiratory | Respiratory |
| Manufacturer | AstraZeneca | Amgen/AstraZeneca |
| Year approved | 2006 | 2021 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $120M | $70M |
| Common side effects | Throat irritation, Oral thrush, Hoarseness, Headache | Sore throat, Joint pain, Back pain, Injection site reactions |
Symbicort
Frequently asked questions
Is Symbicort or Tezspire better?
Neither is universally "better." Symbicort (budesonide/formoterol) and Tezspire (tezepelumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Symbicort and Tezspire?
Symbicort is a ICS/LABA Inhaler made by AstraZeneca, while Tezspire is a TSLP Blocker (Biologic) made by Amgen/AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Symbicort has the larger estimated TV advertising budget of the two.